Insider Buying: ASP Isotopes (NASDAQ:ASPI) Director Purchases $21,600.00 in Stock

Key Points

• Director John Ryan purchased 8,000 ASP Isotopes shares at $2.70 each, investing $21,600 and increasing his direct holdings by 1.23% to 660,222 shares.
• ASP Isotopes traded near $2.63, close to its 12-month low of $2.51 and well below its 12-month high of $14.49. The company reported a quarterly loss of $0.28 per share, missing estimates, despite revenue exceeding forecasts.
• Analyst sentiment is mixed, with an overall “Hold” rating and a $13.00 average price target; institutional investors and hedge funds own 16.8% of the company.

ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) Director John Ryan purchased 8,000 shares of the company's stock in a transaction that occurred on Monday, September 28th. The shares were bought at an average cost of $2.70 per share, with a total value of $21,600.00. Following the transaction, the director directly owned 660,222 shares of the company's stock, valued at $1,782,599.40. The trade was a 1.23% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

ASP Isotopes Stock Performance

ASP Isotopes stock opened at $2.63 on Wednesday. The firm's fifty day moving average price is $3.77 and its 200 day moving average price is $4.93. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.87 and a quick ratio of 3.85. The company has a market capitalization of $403.21 million, a price-to-earnings ratio of -1.99 and a beta of 3.59. ASP Isotopes Inc. has a 12-month low of $2.51 and a 12-month high of $14.49.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.11). The company had revenue of $5.12 million for the quarter, compared to analyst estimates of $4.47 million. ASP Isotopes had a negative return on equity of 64.99% and a negative net margin of 427.98%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Wall Street Zen raised ASP Isotopes from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 22nd. Weiss Ratings reiterated a "sell (d-)" rating on shares of ASP Isotopes in a research report on Monday, September 21st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $13.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ASPI. WINTON GROUP Ltd acquired a new stake in shares of ASP Isotopes in the 2nd quarter valued at $588,000. Integrated Wealth Concepts LLC acquired a new position in shares of ASP Isotopes during the second quarter valued at $176,000. Squarepoint Ops LLC boosted its stake in shares of ASP Isotopes by 75.6% in the 2nd quarter. Squarepoint Ops LLC now owns 123,951 shares of the company's stock valued at $771,000 after purchasing an additional 53,354 shares during the last quarter. Amundi bought a new position in ASP Isotopes in the second quarter valued at approximately $107,000. Finally, AXQ Capital LP acquired a new stake in shares of ASP Isotopes during the second quarter worth $80,000. Institutional investors and hedge funds own 16.80% of the company's stock.

About ASP Isotopes

ASP Isotopes Inc NASDAQ: ASPI is a development-stage company focused on isotope enrichment and related technologies. The company is developing an isotope-separation platform known as the Aerodynamic Separation Process, which is intended to enrich selected chemical elements and isotopes for use in several specialized markets.

ASP Isotopes has identified applications in the nuclear energy, medical, semiconductor, and quantum-computing industries. Its development programs have included uranium enrichment as well as the production of specialty isotopes such as carbon-14, molybdenum-100, and silicon-28.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.